公开(公告)号：EP3358007A1

公开(公告)日：2018-08-08

申请号：EP17211121.3

申请日：2011-07-13

申请人： Celularity, Inc.

发明人： Hariri, Robert J. ,  Heidaran, Mohammad A. ,  Jasko, Stephen ,  Kang, Lin ,  Law, Eric ,  Pal, Ajai ,  Stout, Bhavani ,  Voskinarian-Berse, Vanessa ,  Zeitlin, Andrew ,  Zhang, Xiaokui

IPC分类号： C12N5/0783 ,  A61K35/17 ,  A61K35/12

CPC分类号： C12N5/0646 ,  A61K35/17 ,  A61K2035/124 ,  C12N2500/05 ,  C12N2500/25 ,  C12N2500/33 ,  C12N2500/36 ,  C12N2500/38 ,  C12N2500/44 ,  C12N2500/46 ,  C12N2500/84 ,  C12N2501/125 ,  C12N2501/145 ,  C12N2501/2302 ,  C12N2501/2303 ,  C12N2501/2307 ,  C12N2501/2315 ,  C12N2501/26 ,  C12N2501/59 ,  C12N2501/91 ,  C12N2501/998 ,  C12N2506/11

摘要： Provided herein are in vitro two-step methods of producing populations of activated natural killer (NK) cells, comprising an expansion and a differentiation step. Also provided herein are populations of activated NK cells obtained by the method of the invention, and the use of the same in methods for treating cancer in an individual. Provided herein are also in vitro methods of suppressing the proliferation of tumor cells comprising contacting the tumor cells with a population of NK produced by the methods provided herein.

公开(公告)号：EP3083978A4

公开(公告)日：2017-08-30

申请号：EP14870754

申请日：2014-12-19

申请人： BIO-ESS LABORATORIES LLC

发明人： ELHOFY ADAM ,  WEBER ALLAN

IPC分类号： C12P21/04 ,  A61K9/127 ,  C12N5/00

CPC分类号： C12N5/0018 ,  A01N1/0221 ,  A01N1/0226 ,  C12N5/0037 ,  C12N2500/05 ,  C12N2500/24 ,  C12N2500/32 ,  C12N2500/34 ,  C12N2500/35 ,  C12N2500/36 ,  C12N2500/38 ,  C12N2500/46 ,  C12N2500/50 ,  C12N2500/62 ,  C12N2501/39 ,  C12N2533/32

摘要： The present disclosure relates, in general, to a media, e.g., a serum replacement, media supplement, complete media or cryopreservation media, comprising a base physiological buffer and liposomes comprising cholesterol, phosphatidylcholine and fatty acids. It is contemplated that media provides advantages to improve cell growth in culture compared to cells cultured not using the serum replacement described herein.

摘要翻译： 本公开一般涉及包含基础生理缓冲液和包含胆固醇，磷脂酰胆碱和脂肪酸的脂质体的介质，例如血清替代物，培养基补充物，完全培养基或冷冻保存介质。 预期与不使用本文所述的血清替代物培养的细胞相比，培养基提供了改善培养物中细胞生长的优点。

公开(公告)号：EP2356218B1

公开(公告)日：2017-05-03

申请号：EP09764840

申请日：2009-12-07

申请人： INSERM (INSTITUT NAT DE LA SANTÉ ET DE LA RECH MÉDICALE) ,  ASS FRANCAISE CONTRE LES MYOPATHIES

发明人： BENCHOUA ALEXANDRA ,  PERRIER ANSELME ,  AUBRY LAETITIA

IPC分类号： C12N5/07 ,  A61K35/30 ,  C12N5/0793 ,  C12N5/0797 ,  G01N33/50

CPC分类号： C12N5/0619 ,  A61K35/30 ,  C12N5/0623 ,  C12N2500/05 ,  C12N2500/32 ,  C12N2500/36 ,  C12N2500/38 ,  C12N2500/40 ,  C12N2501/15 ,  C12N2501/155 ,  C12N2501/16 ,  C12N2506/02 ,  C12N2506/45 ,  G01N33/5058

公开(公告)号：EP3036254A1

公开(公告)日：2016-06-29

申请号：EP14752892.1

申请日：2014-08-20

申请人： LEK Pharmaceuticals d.d.

发明人： FICKO TRCEK, Tanja

IPC分类号： C07K16/24 ,  C12N5/00

CPC分类号： C12N5/0018 ,  C07K16/241 ,  C12N2500/05 ,  C12N2500/20 ,  C12N2500/22

摘要： The present invention is related to a cell culture medium for reducing the C-terminal heterogeneity of a polypeptide expressed in cell-culture, wherein the medium comprises at least one essential trace element in an effective amount, and to a cell culture process for reducing C-terminal heterogeneity of a protein, in which process an essential trace element is used.

摘要翻译： 本发明涉及一种细胞培养基用于降低细胞培养过表达多肽，worin所述培养基包含至少一种必需微量元素在有效量的C末端的异质性，以及在细胞培养过程用于减少Ç 的蛋白质的末端异质性，其中使用必需的微量元素的过程。

公开(公告)号：EP2730648B1

公开(公告)日：2016-06-15

申请号：EP13160782.2

申请日：2013-03-25

申请人： Grifols, S.A.

发明人： Diez Cervantes, José Maria ,  Gajardo Rodríguez, Rodrigo

IPC分类号： C12N5/00 ,  C12N5/0775 ,  C12N5/071

CPC分类号： C12N5/0668 ,  C12N5/0663 ,  C12N2500/05 ,  C12N2501/115 ,  C12N2501/33 ,  C12N2502/115

公开(公告)号：EP2817620B1

公开(公告)日：2016-06-01

申请号：EP13709633.5

申请日：2013-02-22

申请人： Verik Bio, Inc.

发明人： PARENTEAU, Nancy, L. ,  LANING, Joseph, C. ,  YOUNG, Janet, H.

IPC分类号： A61K38/17 ,  A61K35/17 ,  C07K14/705 ,  C07K14/74 ,  G01N33/574 ,  G01N33/50 ,  C12N5/0783 ,  C12N5/095 ,  C12N5/09

CPC分类号： G01N33/574 ,  A61K35/17 ,  A61K38/1774 ,  C07K14/70503 ,  C07K14/70539 ,  C12N5/0638 ,  C12N5/0693 ,  C12N5/0695 ,  C12N2500/05 ,  C12N2501/01 ,  C12N2501/2301 ,  C12N2501/24 ,  C12N2501/25 ,  C12N2501/48 ,  C12N2501/90 ,  G01N33/50

摘要： Finding biologically relevant cancer markers is key to developing an effective treatment. Once specific antigens have been identified that are present on the cell population responsible for propagating tumors, T cells can be genetically altered to target these antigens and then used for personalized T cell therapy. A method to identify and select peptide antigens that effectively associate with and are presented by host HLA surface molecules originating from tumor cells responsible for the persistence and propagation of a cancer has been developed. The system of using these data to produce T cells engineered to express T cell receptors recognizing the peptide antigens is used in the production of a personalized adoptive T cell therapy for cancer that eliminates the cells capable of tumor propagation and cancer progression. The system is especially useful in the production of cancer treatments to achieve complete durable remission of cancers of epithelial origin.

公开(公告)号：EP1972685B1

公开(公告)日：2015-09-02

申请号：EP08102779.9

申请日：2008-03-19

申请人： Université Paris Descartes ,  Assistance Publique - Hôpitaux de Paris ,  Inserm

发明人： Gogly, Bruno ,  Coulomb, Bernard ,  Lafont, Antoine

IPC分类号： C12N5/071

CPC分类号： C12N5/0656 ,  C12N2500/05 ,  C12N2500/20 ,  C12N2500/25 ,  C12N2500/32 ,  C12N2500/84 ,  C12N2500/90 ,  C12N2501/115

公开(公告)号：EP2861717A1

公开(公告)日：2015-04-22

申请号：EP13723676.6

申请日：2013-05-17

申请人： Merck Patent GmbH

发明人： VON HAGEN, Joerg

IPC分类号： C12N5/00 ,  C12N5/02

CPC分类号： C12N5/0018 ,  A61K9/141 ,  A61K9/19 ,  B02C23/00 ,  C12N2500/05 ,  C12N2500/10

摘要： The present invention relates to an a process for manufacturing dry powder cell culture media. The preparation and usage of mixed particles generated by co-lyophilisation leads to homogenously blended cell culture media.

公开(公告)号：EP2831222A1

公开(公告)日：2015-02-04

申请号：EP12872506.6

申请日：2012-03-27

申请人： Okinawa Institute of Science and Technology Graduate University

发明人： DIMITROV, Dimitar Ivanov ,  GUILLAUD, Laurent Elie ,  TAOUFIQ, Zacharie Mehdi Francois ,  TAKAHASHI, Tomoyuki

IPC分类号： C12N1/00 ,  C12N5/0793

CPC分类号： C12N5/0619 ,  C12N5/0618 ,  C12N2500/05 ,  C12N2501/115 ,  C12N2501/13 ,  C12N2502/086

摘要： An object of the present invention is to develop and provide a method for producing a neuron model having reproduced in vivo properties by improving a cell culture medium composition and a cell culture medium composition necessary for the production of such neuron model. According to the present invention, cell culture is carried out in vitro using a medium for producing in vivo-like and enhanced synaptogenesis neuron model supplemented with a medium supplement for producing in vivo-like and enhanced synaptogenesis neuron model comprising any or any combination of NT-3, potassium or a salt thereof, and FGF2.

摘要翻译： 本发明的一个目的是开发并提供一种通过改进生产这种神经元模型所必需的细胞培养基组合物和细胞培养基组合物来产生具有复制的体内特性的神经元模型的方法。 根据本发明，使用用于产生体内样和增强的突触发生神经元模型的培养基在体外进行细胞培养，所述神经元模型补充有用于产生体内样和增强的突触发生神经元模型的培养基补充物，所述模型包含任何或任何NT组合 -3，钾或其盐和FGF2。

公开(公告)号：EP2563904B1

公开(公告)日：2015-01-21

申请号：EP11717240.3

申请日：2011-04-25

申请人： Novartis AG

发明人： LEIST, Christian ,  MEISSNER, Petra ,  SCHMIDT, Jörg

IPC分类号： C12N5/00

CPC分类号： C12N5/005 ,  C12N5/0018 ,  C12N2500/05 ,  C12N2500/12